The IDH2 Knockout NCI-H1975 Polyclonal Cells comprise a CRISPR/Cas9-edited polyclonal knockout cell population derived from the NCI-H1975 human lung adenocarcinoma epithelial cell line. This product features targeted disruption of the IDH2 gene, resulting in a heterogeneous mixture of cells with loss-of-function mutations that abolish functional IDH2 protein expression. The polyclonal format reflects the incorporation of diverse editing outcomes without single-cell cloning, providing a robust model to study the collective consequences of IDH2 deficiency in a lung cancer context. These cells are intended for advanced biomedical research into metabolic and epigenetic pathways governed by mitochondrial isocitrate dehydrogenase 2.
The parental NCI-H1975 cell line is a well-characterized model of non-small cell lung carcinoma, originating from a pleural effusion of a female patient with lung adenocarcinoma. It harbors activating EGFR L858R and resistance-associated T790M mutations, making it particularly relevant for investigating mechanisms of EGFR-targeted therapy and acquired resistance. As an adherent, epithelial cell type, NCI-H1975 retains key features of lung adenocarcinoma pathology and is widely employed in cancer biology, drug development, and metabolism studies. This genetic background provides a clinically pertinent platform for examining how IDH2 loss influences tumor cell behavior under EGFR-driven oncogenic signaling.
IDH2 functions in the mitochondrial matrix as a key enzyme of the tricarboxylic acid (TCA) cycle, catalyzing the oxidative decarboxylation of isocitrate to ??-ketoglutarate (??-KG) while generating NADPH from NADP+. This reaction is tightly regulated by several factors, including SIRT3-mediated deacetylation, the NADH/NAD+ ratio, and transcription factors such as HIF1A, MYC, ATF4, and NFE2L2. IDH2-derived ??-KG serves as an obligate co-substrate for dioxygenases, including TET family DNA demethylases and histone lysine demethylases, linking TCA cycle activity to epigenetic regulation. Concomitantly, NADPH produced by IDH2 maintains redox homeostasis via glutathione reductase and supports anabolic biosynthetic pathways. Disruption of IDH2 consequently attenuates NADPH regeneration and ??-KG supply, sensitizing cells to oxidative stress and impairing normal epigenetic control.
In the NCI-H1975 lung adenocarcinoma context, IDH2 knockout introduces significant metabolic and epigenetic vulnerabilities. The EGFR L858R/T790M mutation-driven signaling imposes high demands on anabolic metabolism and redox buffering; loss of IDH2 compromises the cell’s ability to sustain NADPH levels and TCA cycle flux, potentially exacerbating oxidative stress and altering DNA and histone methylation patterns through reduced ??-KG availability. This model enables dissection of how mitochondrial metabolism interfaces with oncogenic signaling cascades, particularly in therapy-resistant lung adenocarcinoma. The polyclonal nature of the knockout population better reflects the heterogeneity observed in tumor environments, providing a more physiologically relevant system for functional studies compared to clonal derivatives.
Typical research applications for these cells encompass diverse experimental strategies. Investigators can employ Western blotting and RT-qPCR to confirm IDH2 disruption, while enzymatic and mass spectrometry-based assays directly quantify ??-KG and NADPH levels. Metabolic flux analyses via Seahorse technology reveal shifts in oxidative phosphorylation and glycolysis. Oxidative stress sensitivity assays, glutathione measurement, and DNA hydroxymethylation profiling (e.g., dot blot or hMeDIP) elucidate redox and epigenetic consequences. Proliferation, colony formation, and apoptosis assays, along with drug sensitivity profiling against EGFR inhibitors, facilitate assessment of synthetic lethality and combination therapy approaches. These studies advance understanding of IDH2??s role in lung adenocarcinoma metabolism and inform therapeutic strategies. For additional technical information, please contact Ascent Research.
